#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1.
1-1	0-2	1.	_	_	_	_

#Text=Introduction
2-1	3-15	Introduction	abstract	new	_	_

#Text=The demand for naturally produced astaxanthin is estimated to witness an exponential growth of 25 % ( CAGR ) by 2025 .
3-1	16-19	The	abstract[2]	new[2]	coref	5-23[18_2]
3-2	20-26	demand	abstract[2]	new[2]	_	_
3-3	27-30	for	abstract[2]	new[2]	_	_
3-4	31-40	naturally	abstract[2]|substance[3]	new[2]|new[3]	coref	5-13[0_3]
3-5	41-49	produced	abstract[2]|substance[3]	new[2]|new[3]	_	_
3-6	50-61	astaxanthin	abstract[2]|substance[3]	new[2]|new[3]	_	_
3-7	62-64	is	_	_	_	_
3-8	65-74	estimated	_	_	_	_
3-9	75-77	to	_	_	_	_
3-10	78-85	witness	_	_	_	_
3-11	86-88	an	abstract[4]	new[4]	_	_
3-12	89-100	exponential	abstract[4]	new[4]	_	_
3-13	101-107	growth	abstract[4]	new[4]	_	_
3-14	108-110	of	abstract[4]	new[4]	_	_
3-15	111-113	25	abstract[4]|quantity[5]	new[4]|new[5]	_	_
3-16	114-115	%	abstract[4]|quantity[5]	new[4]|new[5]	_	_
3-17	116-117	(	_	_	_	_
3-18	118-122	CAGR	abstract	new	_	_
3-19	123-124	)	_	_	_	_
3-20	125-127	by	_	_	_	_
3-21	128-132	2025	time	new	_	_
3-22	133-134	.	_	_	_	_

#Text=This fact is in accordance with a worldwide trend : consumers seek for natural products that are produced in an environmentally friendly way .
4-1	135-139	This	abstract[8]	new[8]	_	_
4-2	140-144	fact	abstract[8]	new[8]	_	_
4-3	145-147	is	_	_	_	_
4-4	148-150	in	_	_	_	_
4-5	151-161	accordance	abstract[9]	new[9]	_	_
4-6	162-166	with	abstract[9]	new[9]	_	_
4-7	167-168	a	abstract[9]|abstract[10]	new[9]|new[10]	_	_
4-8	169-178	worldwide	abstract[9]|abstract[10]	new[9]|new[10]	_	_
4-9	179-184	trend	abstract[9]|abstract[10]	new[9]|new[10]	_	_
4-10	185-186	:	_	_	_	_
4-11	187-196	consumers	person	new	_	_
4-12	197-201	seek	_	_	_	_
4-13	202-205	for	_	_	_	_
4-14	206-213	natural	abstract[12]	new[12]	coref	5-26[20_12]
4-15	214-222	products	abstract[12]	new[12]	_	_
4-16	223-227	that	_	_	_	_
4-17	228-231	are	_	_	_	_
4-18	232-240	produced	_	_	_	_
4-19	241-243	in	_	_	_	_
4-20	244-246	an	abstract[13]	new[13]	_	_
4-21	247-262	environmentally	abstract[13]	new[13]	_	_
4-22	263-271	friendly	abstract[13]	new[13]	_	_
4-23	272-275	way	abstract[13]	new[13]	_	_
4-24	276-277	.	_	_	_	_

#Text=Moreover , the feed industry , which is the main purchaser of astaxanthin , is growing as well in order to satisfy the demand for animal-based food products such as meat , fish and eggs .
5-1	278-286	Moreover	_	_	_	_
5-2	287-288	,	_	_	_	_
5-3	289-292	the	abstract[15]	new[15]	_	_
5-4	293-297	feed	substance|abstract[15]	new|new[15]	_	_
5-5	298-306	industry	abstract[15]	new[15]	_	_
5-6	307-308	,	_	_	_	_
5-7	309-314	which	_	_	_	_
5-8	315-317	is	_	_	_	_
5-9	318-321	the	abstract[16]	new[16]	_	_
5-10	322-326	main	abstract[16]	new[16]	_	_
5-11	327-336	purchaser	abstract[16]	new[16]	_	_
5-12	337-339	of	abstract[16]	new[16]	_	_
5-13	340-351	astaxanthin	abstract[16]|substance	new[16]|giv	coref	6-3
5-14	352-353	,	_	_	_	_
5-15	354-356	is	_	_	_	_
5-16	357-364	growing	_	_	_	_
5-17	365-367	as	_	_	_	_
5-18	368-372	well	_	_	_	_
5-19	373-375	in	_	_	_	_
5-20	376-381	order	_	_	_	_
5-21	382-384	to	_	_	_	_
5-22	385-392	satisfy	_	_	_	_
5-23	393-396	the	abstract[18]	giv[18]	coref	6-24[31_18]
5-24	397-403	demand	abstract[18]	giv[18]	_	_
5-25	404-407	for	abstract[18]	giv[18]	_	_
5-26	408-420	animal-based	abstract[18]|abstract[20]	giv[18]|giv[20]	_	_
5-27	421-425	food	abstract[18]|substance|abstract[20]	giv[18]|new|giv[20]	coref	7-6
5-28	426-434	products	abstract[18]|abstract[20]	giv[18]|giv[20]	_	_
5-29	435-439	such	abstract[18]|abstract[20]	giv[18]|giv[20]	_	_
5-30	440-442	as	abstract[18]|abstract[20]	giv[18]|giv[20]	_	_
5-31	443-447	meat	abstract[18]|abstract[20]|substance	giv[18]|giv[20]|new	_	_
5-32	448-449	,	abstract[18]|abstract[20]	giv[18]|giv[20]	_	_
5-33	450-454	fish	abstract[18]|abstract[20]|animal	giv[18]|giv[20]|new	_	_
5-34	455-458	and	abstract[18]|abstract[20]	giv[18]|giv[20]	_	_
5-35	459-463	eggs	abstract[18]|abstract[20]|object	giv[18]|giv[20]|new	_	_
5-36	464-465	.	_	_	_	_

#Text=As the astaxanthin market is dominated by synthetic astaxanthin that is made from petro chemistry , new production capacities are needed to meet the increasing demand for naturally produced astaxanthin .
6-1	466-468	As	_	_	_	_
6-2	469-472	the	abstract[25]	new[25]	_	_
6-3	473-484	astaxanthin	substance|abstract[25]	giv|new[25]	coref	6-8[26_0]
6-4	485-491	market	abstract[25]	new[25]	_	_
6-5	492-494	is	_	_	_	_
6-6	495-504	dominated	_	_	_	_
6-7	505-507	by	_	_	_	_
6-8	508-517	synthetic	substance[26]	giv[26]	coref	6-28[32_26]
6-9	518-529	astaxanthin	substance[26]	giv[26]	_	_
6-10	530-534	that	_	_	_	_
6-11	535-537	is	_	_	_	_
6-12	538-542	made	_	_	_	_
6-13	543-547	from	_	_	_	_
6-14	548-553	petro	organization|substance[28]	new|new[28]	_	_
6-15	554-563	chemistry	substance[28]	new[28]	_	_
6-16	564-565	,	_	_	_	_
6-17	566-569	new	abstract[30]	new[30]	_	_
6-18	570-580	production	abstract|abstract[30]	new|new[30]	coref	7-13[38_0]
6-19	581-591	capacities	abstract[30]	new[30]	_	_
6-20	592-595	are	_	_	_	_
6-21	596-602	needed	_	_	_	_
6-22	603-605	to	_	_	_	_
6-23	606-610	meet	_	_	_	_
6-24	611-614	the	abstract[31]	giv[31]	_	_
6-25	615-625	increasing	abstract[31]	giv[31]	_	_
6-26	626-632	demand	abstract[31]	giv[31]	_	_
6-27	633-636	for	abstract[31]	giv[31]	_	_
6-28	637-646	naturally	abstract[31]|substance[32]	giv[31]|giv[32]	coref	15-23[93_32]
6-29	647-655	produced	abstract[31]|substance[32]	giv[31]|giv[32]	_	_
6-30	656-667	astaxanthin	abstract[31]|substance[32]	giv[31]|giv[32]	_	_
6-31	668-669	.	_	_	_	_

#Text=Fermentations with Corynebacterium glutamicum dominate food and feed biotechnology since decades for the production of amino acids e.g. l-glutamate and l-lysine .
7-1	670-683	Fermentations	substance[33]	new[33]	coref	24-19[152_33]
7-2	684-688	with	substance[33]	new[33]	_	_
7-3	689-704	Corynebacterium	substance[33]|animal	new[33]|new	_	_
7-4	705-715	glutamicum	substance[33]	new[33]	_	_
7-5	716-724	dominate	_	_	_	_
7-6	725-729	food	substance	giv	_	_
7-7	730-733	and	_	_	_	_
7-8	734-738	feed	_	_	_	_
7-9	739-752	biotechnology	abstract	new	_	_
7-10	753-758	since	_	_	_	_
7-11	759-766	decades	time	new	_	_
7-12	767-770	for	_	_	_	_
7-13	771-774	the	abstract[38]	giv[38]	_	_
7-14	775-785	production	abstract[38]	giv[38]	_	_
7-15	786-788	of	abstract[38]	giv[38]	_	_
7-16	789-794	amino	abstract[38]|abstract[39]	giv[38]|new[39]	appos	7-21[0_39]
7-17	795-800	acids	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
7-18	801-805	e.g.	_	_	_	_
7-19	806-817	l-glutamate	_	_	_	_
7-20	818-821	and	_	_	_	_
7-21	822-830	l-lysine	abstract	giv	_	_
7-22	831-832	.	_	_	_	_

#Text=This microorganism naturally synthesizes carotenoids as pigments and yet investigations concerning this output are limited .
8-1	833-837	This	animal[41]	new[41]	_	_
8-2	838-851	microorganism	animal[41]	new[41]	_	_
8-3	852-861	naturally	_	_	_	_
8-4	862-873	synthesizes	_	_	_	_
8-5	874-885	carotenoids	substance	new	coref	12-16[82_0]
8-6	886-888	as	_	_	_	_
8-7	889-897	pigments	_	_	_	_
8-8	898-901	and	_	_	_	_
8-9	902-905	yet	_	_	_	_
8-10	906-920	investigations	_	_	_	_
8-11	921-931	concerning	_	_	_	_
8-12	932-936	this	abstract[43]	new[43]	_	_
8-13	937-943	output	abstract[43]	new[43]	_	_
8-14	944-947	are	_	_	_	_
8-15	948-955	limited	_	_	_	_
8-16	956-957	.	_	_	_	_

#Text=The carotenoid/terpenoid precursors dimethylallyl pyrophosphate ( DMAPP ) and isopentenyl pyrophosphate ( IPP ) are derived from the MEP-pathway in this organism . Carotenoid biosynthesis of the natural C50 carotenoid decaprenoxanthin is based on the accumulation of the C40 intermediate lycopene .
9-1	958-961	The	person[45]	new[45]	appos	9-4[46_45]
9-2	962-982	carotenoid/terpenoid	object|person[45]	new|new[45]	_	_
9-3	983-993	precursors	person[45]	new[45]	_	_
9-4	994-1007	dimethylallyl	person[46]	giv[46]	_	_
9-5	1008-1021	pyrophosphate	person[46]	giv[46]	_	_
9-6	1022-1023	(	_	_	_	_
9-7	1024-1029	DMAPP	abstract	new	_	_
9-8	1030-1031	)	_	_	_	_
9-9	1032-1035	and	_	_	_	_
9-10	1036-1047	isopentenyl	abstract|abstract[49]	new|new[49]	appos|appos	9-13[0_49]|9-13[0_49]
9-11	1048-1061	pyrophosphate	abstract[49]	new[49]	_	_
9-12	1062-1063	(	_	_	_	_
9-13	1064-1067	IPP	abstract	giv	_	_
9-14	1068-1069	)	_	_	_	_
9-15	1070-1073	are	_	_	_	_
9-16	1074-1081	derived	_	_	_	_
9-17	1082-1086	from	_	_	_	_
9-18	1087-1090	the	abstract[51]	new[51]	_	_
9-19	1091-1102	MEP-pathway	abstract[51]	new[51]	_	_
9-20	1103-1105	in	_	_	_	_
9-21	1106-1110	this	animal[52]	new[52]	_	_
9-22	1111-1119	organism	animal[52]	new[52]	_	_
9-23	1120-1121	.	_	_	_	_
9-24	1122-1132	Carotenoid	abstract[53]	new[53]	_	_
9-25	1133-1145	biosynthesis	abstract[53]	new[53]	_	_
9-26	1146-1148	of	abstract[53]	new[53]	_	_
9-27	1149-1152	the	abstract[53]|object[56]	new[53]|new[56]	_	_
9-28	1153-1160	natural	abstract[53]|object[56]	new[53]|new[56]	_	_
9-29	1161-1164	C50	abstract[53]|time|object[56]	new[53]|new|new[56]	_	_
9-30	1165-1175	carotenoid	abstract[53]|object|object[56]	new[53]|new|new[56]	coref	10-9
9-31	1176-1192	decaprenoxanthin	abstract[53]|object[56]	new[53]|new[56]	_	_
9-32	1193-1195	is	_	_	_	_
9-33	1196-1201	based	_	_	_	_
9-34	1202-1204	on	_	_	_	_
9-35	1205-1208	the	event[57]	new[57]	_	_
9-36	1209-1221	accumulation	event[57]	new[57]	_	_
9-37	1222-1224	of	event[57]	new[57]	_	_
9-38	1225-1228	the	event[57]|substance[59]	new[57]|new[59]	_	_
9-39	1229-1232	C40	event[57]|abstract|substance[59]	new[57]|new|new[59]	coref	15-17[91_0]
9-40	1233-1245	intermediate	event[57]|substance[59]	new[57]|new[59]	_	_
9-41	1246-1254	lycopene	event[57]|substance[59]	new[57]|new[59]	_	_
9-42	1255-1256	.	_	_	_	_

#Text=The genome of C. glutamicum contains a major carotenoid operon and the regulatory mechanism involving a MarR-type transcriptional regulator CrtR was identified .
10-1	1257-1260	The	object[60]	new[60]	_	_
10-2	1261-1267	genome	object[60]	new[60]	_	_
10-3	1268-1270	of	object[60]	new[60]	_	_
10-4	1271-1273	C.	object[60]|person[61]	new[60]|new[61]	coref	15-8[0_61]
10-5	1274-1284	glutamicum	object[60]|person[61]	new[60]|new[61]	_	_
10-6	1285-1293	contains	_	_	_	_
10-7	1294-1295	a	abstract[63]	new[63]	_	_
10-8	1296-1301	major	abstract[63]	new[63]	_	_
10-9	1302-1312	carotenoid	object|abstract[63]	giv|new[63]	coref	11-15
10-10	1313-1319	operon	abstract[63]	new[63]	_	_
10-11	1320-1323	and	_	_	_	_
10-12	1324-1327	the	abstract[64]	new[64]	_	_
10-13	1328-1338	regulatory	abstract[64]	new[64]	_	_
10-14	1339-1348	mechanism	abstract[64]	new[64]	_	_
10-15	1349-1358	involving	_	_	_	_
10-16	1359-1360	a	substance[66]	new[66]	_	_
10-17	1361-1370	MarR-type	abstract|substance[66]	new|new[66]	_	_
10-18	1371-1386	transcriptional	substance[66]	new[66]	_	_
10-19	1387-1396	regulator	substance[66]	new[66]	_	_
10-20	1397-1401	CrtR	abstract	new	coref	11-29[78_0]
10-21	1402-1405	was	_	_	_	_
10-22	1406-1416	identified	_	_	_	_
10-23	1417-1418	.	_	_	_	_

#Text=Interestingly , this regulation is working in a metabolite dependent manner in which the carotenoid precursor molecule geranylgeranyl pyrophosphate ( GGPP ) is acting as an effector of the repressor CrtR .
11-1	1419-1432	Interestingly	_	_	_	_
11-2	1433-1434	,	_	_	_	_
11-3	1435-1439	this	abstract[68]	new[68]	_	_
11-4	1440-1450	regulation	abstract[68]	new[68]	_	_
11-5	1451-1453	is	_	_	_	_
11-6	1454-1461	working	_	_	_	_
11-7	1462-1464	in	_	_	_	_
11-8	1465-1466	a	abstract[69]	new[69]	_	_
11-9	1467-1477	metabolite	abstract[69]	new[69]	_	_
11-10	1478-1487	dependent	abstract[70]	new[70]	_	_
11-11	1488-1494	manner	abstract[70]	new[70]	_	_
11-12	1495-1497	in	_	_	_	_
11-13	1498-1503	which	_	_	_	_
11-14	1504-1507	the	person[75]	new[75]	coref	19-8[0_75]
11-15	1508-1518	carotenoid	object|person[72]|person[75]	giv|new[72]|new[75]	coref|coref	19-15|19-15
11-16	1519-1528	precursor	person[72]|person[75]	new[72]|new[75]	_	_
11-17	1529-1537	molecule	abstract|person[75]	new|new[75]	_	_
11-18	1538-1552	geranylgeranyl	abstract|person[75]	new|new[75]	coref	19-7
11-19	1553-1566	pyrophosphate	person[75]	new[75]	_	_
11-20	1567-1568	(	_	_	_	_
11-21	1569-1573	GGPP	substance	new	_	_
11-22	1574-1575	)	_	_	_	_
11-23	1576-1578	is	_	_	_	_
11-24	1579-1585	acting	_	_	_	_
11-25	1586-1588	as	_	_	_	_
11-26	1589-1591	an	_	_	_	_
11-27	1592-1600	effector	_	_	_	_
11-28	1601-1603	of	_	_	_	_
11-29	1604-1607	the	abstract[78]	giv[78]	_	_
11-30	1608-1617	repressor	object|abstract[78]	new|giv[78]	_	_
11-31	1618-1622	CrtR	abstract[78]	giv[78]	_	_
11-32	1623-1624	.	_	_	_	_

#Text=Thus , as the genetic background was analyzed in more detail , the production of industrially relevant carotenoids of the C40 family was conducted over the last years (
12-1	1625-1629	Thus	_	_	_	_
12-2	1630-1631	,	_	_	_	_
12-3	1632-1634	as	_	_	_	_
12-4	1635-1638	the	abstract[79]	new[79]	_	_
12-5	1639-1646	genetic	abstract[79]	new[79]	_	_
12-6	1647-1657	background	abstract[79]	new[79]	_	_
12-7	1658-1661	was	_	_	_	_
12-8	1662-1670	analyzed	_	_	_	_
12-9	1671-1673	in	_	_	_	_
12-10	1674-1678	more	abstract[80]	new[80]	_	_
12-11	1679-1685	detail	abstract[80]	new[80]	_	_
12-12	1686-1687	,	_	_	_	_
12-13	1688-1691	the	abstract[81]	new[81]	_	_
12-14	1692-1702	production	abstract[81]	new[81]	_	_
12-15	1703-1705	of	abstract[81]	new[81]	_	_
12-16	1706-1718	industrially	abstract[81]|substance[82]	new[81]|giv[82]	coref	15-20[92_82]
12-17	1719-1727	relevant	abstract[81]|substance[82]	new[81]|giv[82]	_	_
12-18	1728-1739	carotenoids	abstract[81]|substance[82]	new[81]|giv[82]	_	_
12-19	1740-1742	of	abstract[81]|substance[82]	new[81]|giv[82]	_	_
12-20	1743-1746	the	abstract[81]|substance[82]|abstract[83]	new[81]|giv[82]|new[83]	_	_
12-21	1747-1750	C40	abstract[81]|substance[82]|abstract[83]	new[81]|giv[82]|new[83]	_	_
12-22	1751-1757	family	abstract[81]|substance[82]|abstract[83]	new[81]|giv[82]|new[83]	_	_
12-23	1758-1761	was	_	_	_	_
12-24	1762-1771	conducted	_	_	_	_
12-25	1772-1776	over	_	_	_	_
12-26	1777-1780	the	time[84]	new[84]	_	_
12-27	1781-1785	last	time[84]	new[84]	_	_
12-28	1786-1791	years	time[84]	new[84]	_	_
12-29	1792-1793	(	_	_	_	_

#Text=Figure 1
13-1	1794-1800	Figure	object[85]	new[85]	_	_
13-2	1801-1802	1	object[85]	new[85]	_	_

#Text=) .
14-1	1803-1804	)	_	_	_	_
14-2	1805-1806	.	_	_	_	_

#Text=Indeed , metabolic engineering studies showed that C. glutamicum is a suitable host for production of various C40 and C50 carotenoids with astaxanthin as prominant example .
15-1	1807-1813	Indeed	_	_	_	_
15-2	1814-1815	,	_	_	_	_
15-3	1816-1825	metabolic	abstract[87]	new[87]	_	_
15-4	1826-1837	engineering	abstract|abstract[87]	new|new[87]	coref	25-7
15-5	1838-1845	studies	abstract[87]	new[87]	_	_
15-6	1846-1852	showed	_	_	_	_
15-7	1853-1857	that	_	_	_	_
15-8	1858-1860	C.	person	giv	coref	23-16
15-9	1861-1871	glutamicum	_	_	_	_
15-10	1872-1874	is	_	_	_	_
15-11	1875-1876	a	person[89]	new[89]	_	_
15-12	1877-1885	suitable	person[89]	new[89]	_	_
15-13	1886-1890	host	person[89]	new[89]	_	_
15-14	1891-1894	for	person[89]	new[89]	_	_
15-15	1895-1905	production	person[89]|abstract[90]	new[89]|new[90]	coref	16-14[98_90]
15-16	1906-1908	of	person[89]|abstract[90]	new[89]|new[90]	_	_
15-17	1909-1916	various	person[89]|abstract[90]|abstract[91]	new[89]|new[90]|giv[91]	_	_
15-18	1917-1920	C40	person[89]|abstract[90]|abstract[91]	new[89]|new[90]|giv[91]	_	_
15-19	1921-1924	and	person[89]|abstract[90]	new[89]|new[90]	_	_
15-20	1925-1928	C50	person[89]|abstract[90]|substance[92]	new[89]|new[90]|giv[92]	_	_
15-21	1929-1940	carotenoids	person[89]|abstract[90]|substance[92]	new[89]|new[90]|giv[92]	_	_
15-22	1941-1945	with	person[89]|abstract[90]|substance[92]	new[89]|new[90]|giv[92]	_	_
15-23	1946-1957	astaxanthin	person[89]|abstract[90]|substance[92]|substance[93]	new[89]|new[90]|giv[92]|giv[93]	coref	18-18[0_93]
15-24	1958-1960	as	person[89]|abstract[90]|substance[92]|substance[93]	new[89]|new[90]|giv[92]|giv[93]	_	_
15-25	1961-1970	prominant	person[89]|abstract[90]|substance[92]|substance[93]	new[89]|new[90]|giv[92]|giv[93]	_	_
15-26	1971-1978	example	person[89]|abstract[90]|substance[92]|substance[93]	new[89]|new[90]|giv[92]|giv[93]	_	_
15-27	1979-1980	.	_	_	_	_

#Text=The previously published strain ASTA1 possesses a good volumetric productivity , but for industrial scale production further improvement is needed in order to meet economically feasible production titers .
16-1	1981-1984	The	abstract[94]	new[94]	_	_
16-2	1985-1995	previously	abstract[94]	new[94]	_	_
16-3	1996-2005	published	abstract[94]	new[94]	_	_
16-4	2006-2012	strain	abstract[94]	new[94]	_	_
16-5	2013-2018	ASTA1	abstract	new	_	_
16-6	2019-2028	possesses	_	_	_	_
16-7	2029-2030	a	abstract[96]	new[96]	_	_
16-8	2031-2035	good	abstract[96]	new[96]	_	_
16-9	2036-2046	volumetric	abstract[96]	new[96]	_	_
16-10	2047-2059	productivity	abstract[96]	new[96]	_	_
16-11	2060-2061	,	_	_	_	_
16-12	2062-2065	but	_	_	_	_
16-13	2066-2069	for	_	_	_	_
16-14	2070-2080	industrial	abstract[98]	giv[98]	coref	16-27[0_98]
16-15	2081-2086	scale	abstract|abstract[98]	new|giv[98]	_	_
16-16	2087-2097	production	abstract[98]	giv[98]	_	_
16-17	2098-2105	further	abstract[99]	new[99]	_	_
16-18	2106-2117	improvement	abstract[99]	new[99]	_	_
16-19	2118-2120	is	_	_	_	_
16-20	2121-2127	needed	_	_	_	_
16-21	2128-2130	in	_	_	_	_
16-22	2131-2136	order	_	_	_	_
16-23	2137-2139	to	_	_	_	_
16-24	2140-2144	meet	_	_	_	_
16-25	2145-2157	economically	abstract[101]	new[101]	_	_
16-26	2158-2166	feasible	abstract[101]	new[101]	_	_
16-27	2167-2177	production	abstract|abstract[101]	giv|new[101]	coref	18-18[119_0]
16-28	2178-2184	titers	abstract[101]	new[101]	_	_
16-29	2185-2186	.	_	_	_	_

#Text=The construction of fusion proteins and the application of membrane anchors was shown to be an efficient strategy to increase membrane integrity and protein stability .
17-1	2187-2190	The	event[102]	new[102]	_	_
17-2	2191-2203	construction	event[102]	new[102]	_	_
17-3	2204-2206	of	event[102]	new[102]	_	_
17-4	2207-2213	fusion	event[102]|object[103]	new[102]|new[103]	coref	25-15[158_103]
17-5	2214-2222	proteins	event[102]|object[103]	new[102]|new[103]	_	_
17-6	2223-2226	and	event[102]	new[102]	_	_
17-7	2227-2230	the	event[102]|event[104]	new[102]|new[104]	ana	18-1[0_104]
17-8	2231-2242	application	event[102]|event[104]	new[102]|new[104]	_	_
17-9	2243-2245	of	event[102]|event[104]	new[102]|new[104]	_	_
17-10	2246-2254	membrane	event[102]|event[104]|object|object[106]	new[102]|new[104]|new|new[106]	coref|coref	17-21|17-21
17-11	2255-2262	anchors	event[102]|event[104]|object[106]	new[102]|new[104]|new[106]	_	_
17-12	2263-2266	was	_	_	_	_
17-13	2267-2272	shown	_	_	_	_
17-14	2273-2275	to	_	_	_	_
17-15	2276-2278	be	_	_	_	_
17-16	2279-2281	an	abstract[107]	new[107]	coref	21-5[139_107]
17-17	2282-2291	efficient	abstract[107]	new[107]	_	_
17-18	2292-2300	strategy	abstract[107]	new[107]	_	_
17-19	2301-2303	to	_	_	_	_
17-20	2304-2312	increase	_	_	_	_
17-21	2313-2321	membrane	object|abstract[109]	giv|new[109]	_	_
17-22	2322-2331	integrity	abstract[109]	new[109]	_	_
17-23	2332-2335	and	_	_	_	_
17-24	2336-2343	protein	substance|abstract[111]	new|new[111]	coref|coref	18-11[117_0]|18-11[117_0]
17-25	2344-2353	stability	abstract[111]	new[111]	_	_
17-26	2354-2355	.	_	_	_	_

#Text=It was shown that linkage of CrtW and CrtZ with the GlpF protein from E. coli increased astaxanthin production by approximately 2-fold .
18-1	2356-2358	It	event	giv	_	_
18-2	2359-2362	was	_	_	_	_
18-3	2363-2368	shown	_	_	_	_
18-4	2369-2373	that	abstract[113]	new[113]	_	_
18-5	2374-2381	linkage	abstract[113]	new[113]	_	_
18-6	2382-2384	of	abstract[113]	new[113]	_	_
18-7	2385-2389	CrtW	abstract[113]|substance	new[113]|new	_	_
18-8	2390-2393	and	abstract[113]	new[113]	_	_
18-9	2394-2398	CrtZ	abstract[113]|substance	new[113]|new	_	_
18-10	2399-2403	with	_	_	_	_
18-11	2404-2407	the	substance[117]	giv[117]	coref	21-7[0_117]
18-12	2408-2412	GlpF	object|substance[117]	new|giv[117]	_	_
18-13	2413-2420	protein	substance[117]	giv[117]	_	_
18-14	2421-2425	from	substance[117]	giv[117]	_	_
18-15	2426-2428	E.	substance[117]	giv[117]	_	_
18-16	2429-2433	coli	substance[117]	giv[117]	_	_
18-17	2434-2443	increased	_	_	_	_
18-18	2444-2455	astaxanthin	substance|abstract[119]	giv|giv[119]	coref|coref|coref|coref	19-15[127_119]|20-14|19-15[127_119]|20-14
18-19	2456-2466	production	abstract[119]	giv[119]	_	_
18-20	2467-2469	by	_	_	_	_
18-21	2470-2483	approximately	_	_	_	_
18-22	2484-2490	2-fold	_	_	_	_
18-23	2491-2492	.	_	_	_	_

#Text=Moreover , the fusion of a geranylgeranyl pyrophosphate synthase with a phytoene synthase improved carotenoid production in plant cells .
19-1	2493-2501	Moreover	event[120]	new[120]	ana	20-3[0_120]
19-2	2502-2503	,	event[120]	new[120]	_	_
19-3	2504-2507	the	event[120]	new[120]	_	_
19-4	2508-2514	fusion	event[120]	new[120]	_	_
19-5	2515-2517	of	event[120]	new[120]	_	_
19-6	2518-2519	a	event[120]|substance[123]	new[120]|new[123]	_	_
19-7	2520-2534	geranylgeranyl	event[120]|abstract|substance[123]	new[120]|giv|new[123]	_	_
19-8	2535-2548	pyrophosphate	event[120]|person|substance[123]	new[120]|giv|new[123]	_	_
19-9	2549-2557	synthase	event[120]|substance[123]	new[120]|new[123]	_	_
19-10	2558-2562	with	event[120]|substance[123]	new[120]|new[123]	_	_
19-11	2563-2564	a	event[120]|substance[123]|substance[125]	new[120]|new[123]|new[125]	_	_
19-12	2565-2573	phytoene	event[120]|substance[123]|abstract|substance[125]	new[120]|new[123]|new|new[125]	_	_
19-13	2574-2582	synthase	event[120]|substance[123]|substance[125]	new[120]|new[123]|new[125]	_	_
19-14	2583-2591	improved	event[120]|substance[123]	new[120]|new[123]	_	_
19-15	2592-2602	carotenoid	event[120]|substance[123]|object|abstract[127]	new[120]|new[123]|giv|giv[127]	coref|coref|coref|coref	20-11|20-14[135_127]|20-11|20-14[135_127]
19-16	2603-2613	production	event[120]|substance[123]|abstract[127]	new[120]|new[123]|giv[127]	_	_
19-17	2614-2616	in	event[120]|substance[123]|abstract[127]	new[120]|new[123]|giv[127]	_	_
19-18	2617-2622	plant	event[120]|substance[123]|abstract[127]|object|object[129]	new[120]|new[123]|giv[127]|new|new[129]	_	_
19-19	2623-2628	cells	event[120]|substance[123]|abstract[127]|object[129]	new[120]|new[123]|giv[127]|new[129]	_	_
19-20	2629-2630	.	_	_	_	_

#Text=Recently , it was shown that fusion of the terminal carotenoid enzymes increased astaxanthin production in E. coli .
20-1	2631-2639	Recently	_	_	_	_
20-2	2640-2641	,	_	_	_	_
20-3	2642-2644	it	event	giv	_	_
20-4	2645-2648	was	_	_	_	_
20-5	2649-2654	shown	_	_	_	_
20-6	2655-2659	that	_	_	_	_
20-7	2660-2666	fusion	event[131]	new[131]	coref	21-6[0_131]
20-8	2667-2669	of	event[131]	new[131]	_	_
20-9	2670-2673	the	event[131]|substance[133]	new[131]|new[133]	_	_
20-10	2674-2682	terminal	event[131]|substance[133]	new[131]|new[133]	_	_
20-11	2683-2693	carotenoid	event[131]|abstract|substance[133]	new[131]|giv|new[133]	_	_
20-12	2694-2701	enzymes	event[131]|substance[133]	new[131]|new[133]	_	_
20-13	2702-2711	increased	_	_	_	_
20-14	2712-2723	astaxanthin	substance|abstract[135]	giv|giv[135]	coref|coref|coref|coref	23-9|23-5[142_135]|23-9|23-5[142_135]
20-15	2724-2734	production	abstract[135]	giv[135]	_	_
20-16	2735-2737	in	_	_	_	_
20-17	2738-2740	E.	_	_	_	_
20-18	2741-2745	coli	_	_	_	_
20-19	2746-2747	.	_	_	_	_

#Text=In this study , a fusion protein strategy was conducted (
21-1	2748-2750	In	_	_	_	_
21-2	2751-2755	this	event[136]	new[136]	_	_
21-3	2756-2761	study	event[136]	new[136]	_	_
21-4	2762-2763	,	_	_	_	_
21-5	2764-2765	a	abstract[139]	giv[139]	_	_
21-6	2766-2772	fusion	event|abstract[139]	giv|giv[139]	coref	25-15
21-7	2773-2780	protein	substance|abstract[139]	giv|giv[139]	_	_
21-8	2781-2789	strategy	abstract[139]	giv[139]	_	_
21-9	2790-2793	was	_	_	_	_
21-10	2794-2803	conducted	_	_	_	_
21-11	2804-2805	(	_	_	_	_

#Text=Figure 2
22-1	2806-2812	Figure	abstract[140]	new[140]	_	_
22-2	2813-2814	2	abstract[140]	new[140]	_	_

#Text=) that resulted in an approximately five-fold improved astaxanthin production under high glucose concentration in C. glutamicum .
23-1	2815-2816	)	_	_	_	_
23-2	2817-2821	that	_	_	_	_
23-3	2822-2830	resulted	_	_	_	_
23-4	2831-2833	in	_	_	_	_
23-5	2834-2836	an	abstract[142]	giv[142]	coref	24-16[151_142]
23-6	2837-2850	approximately	abstract[142]	giv[142]	_	_
23-7	2851-2860	five-fold	abstract[142]	giv[142]	_	_
23-8	2861-2869	improved	abstract[142]	giv[142]	_	_
23-9	2870-2881	astaxanthin	substance|abstract[142]	giv|giv[142]	coref	24-16
23-10	2882-2892	production	abstract[142]	giv[142]	_	_
23-11	2893-2898	under	_	_	_	_
23-12	2899-2903	high	abstract[144]	new[144]	_	_
23-13	2904-2911	glucose	substance|abstract[144]	new|new[144]	coref	24-10
23-14	2912-2925	concentration	abstract[144]	new[144]	_	_
23-15	2926-2928	in	abstract[144]	new[144]	_	_
23-16	2929-2931	C.	abstract[144]|person	new[144]|giv	_	_
23-17	2932-2942	glutamicum	abstract[144]	new[144]	_	_
23-18	2943-2944	.	_	_	_	_

#Text=Moreover , it turned out that the co-utilization of glucose and potassium acetate significantly improved astaxanthin production in small-scale fermentations .
24-1	2945-2953	Moreover	_	_	_	_
24-2	2954-2955	,	_	_	_	_
24-3	2956-2958	it	_	_	_	_
24-4	2959-2965	turned	_	_	_	_
24-5	2966-2969	out	_	_	_	_
24-6	2970-2974	that	_	_	_	_
24-7	2975-2978	the	abstract[146]	new[146]	_	_
24-8	2979-2993	co-utilization	abstract[146]	new[146]	_	_
24-9	2994-2996	of	abstract[146]	new[146]	_	_
24-10	2997-3004	glucose	abstract[146]|substance	new[146]|giv	_	_
24-11	3005-3008	and	abstract[146]	new[146]	_	_
24-12	3009-3018	potassium	abstract[146]|event|substance[149]	new[146]|new|new[149]	_	_
24-13	3019-3026	acetate	abstract[146]|substance[149]	new[146]|new[149]	_	_
24-14	3027-3040	significantly	_	_	_	_
24-15	3041-3049	improved	_	_	_	_
24-16	3050-3061	astaxanthin	substance|abstract[151]	giv|giv[151]	_	_
24-17	3062-3072	production	abstract[151]	giv[151]	_	_
24-18	3073-3075	in	abstract[151]	giv[151]	_	_
24-19	3076-3087	small-scale	abstract[151]|substance[152]	giv[151]|giv[152]	_	_
24-20	3088-3101	fermentations	abstract[151]|substance[152]	giv[151]|giv[152]	_	_
24-21	3102-3103	.	_	_	_	_

#Text=Thus , not only classical metabolic engineering strategies , but also the construction of fusion proteins and the optimization of cultivation media are powerful strategies to exploit the potential of valuable compound formation .
25-1	3104-3108	Thus	_	_	_	_
25-2	3109-3110	,	_	_	_	_
25-3	3111-3114	not	_	_	_	_
25-4	3115-3119	only	abstract[155]	new[155]	_	_
25-5	3120-3129	classical	abstract[155]	new[155]	_	_
25-6	3130-3139	metabolic	person|abstract[155]	new|new[155]	_	_
25-7	3140-3151	engineering	abstract|abstract[155]	giv|new[155]	_	_
25-8	3152-3162	strategies	abstract[155]	new[155]	_	_
25-9	3163-3164	,	_	_	_	_
25-10	3165-3168	but	_	_	_	_
25-11	3169-3173	also	_	_	_	_
25-12	3174-3177	the	abstract[156]	new[156]	coref	25-24[162_156]
25-13	3178-3190	construction	abstract[156]	new[156]	_	_
25-14	3191-3193	of	abstract[156]	new[156]	_	_
25-15	3194-3200	fusion	abstract[156]|event|substance[158]	new[156]|giv|giv[158]	_	_
25-16	3201-3209	proteins	abstract[156]|substance[158]	new[156]|giv[158]	_	_
25-17	3210-3213	and	abstract[156]	new[156]	_	_
25-18	3214-3217	the	abstract[156]|event[159]	new[156]|new[159]	_	_
25-19	3218-3230	optimization	abstract[156]|event[159]	new[156]|new[159]	_	_
25-20	3231-3233	of	abstract[156]|event[159]	new[156]|new[159]	_	_
25-21	3234-3245	cultivation	abstract[156]|event[159]|plant|abstract[161]	new[156]|new[159]|new|new[161]	_	_
25-22	3246-3251	media	abstract[156]|event[159]|abstract[161]	new[156]|new[159]|new[161]	_	_
25-23	3252-3255	are	_	_	_	_
25-24	3256-3264	powerful	abstract[162]	giv[162]	_	_
25-25	3265-3275	strategies	abstract[162]	giv[162]	_	_
25-26	3276-3278	to	_	_	_	_
25-27	3279-3286	exploit	_	_	_	_
25-28	3287-3290	the	abstract[163]	new[163]	_	_
25-29	3291-3300	potential	abstract[163]	new[163]	_	_
25-30	3301-3303	of	abstract[163]	new[163]	_	_
25-31	3304-3312	valuable	abstract[163]|abstract[165]	new[163]|new[165]	_	_
25-32	3313-3321	compound	abstract[163]|place|abstract[165]	new[163]|new|new[165]	_	_
25-33	3322-3331	formation	abstract[163]|abstract[165]	new[163]|new[165]	_	_
25-34	3332-3333	.	_	_	_	_
